| INTRODUCTION
The "real prevalence" of fatty liver (FL) with its different clinical and histological forms is still to be defined, although the prevalence of obesity and diabetes are booming. What is still lacking is a clear definition of these disorders and non-invasive, reliable and affordable tests to distinguish simply non-alcoholic fatty liver (NAFL) from non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). The aim of this article is to review critically what we know and what we should do to define the dimension of the problem, the terminology, and how to reduce and prevent this potentially life-threatening disease. liver fat that is not due to alcohol consumption, without signs of inflammation or fibrosis. Primary NAFLD/NASH is commonly associated with insulin resistance or metabolic liver diseases such as diabetes, obesity and dyslipidemia, 2, 3 and it is now considered to be the hepatic manifestation of the metabolic syndrome (MS). However, there is also a non-insulin resistance primary NAFLD/NASH of either genetic or cryptogenic aetiology (see Table 1 ) and a secondary NAFLD/NASH.
| THE NEED FOR A NEW POSITIVE DEFINITION
Definitions of the difference between alcoholic and non-alcoholic fatty liver diseases (AFLD vs NAFLD) are associated with significant methodological limitations including inadequate adjustment for confounding factors, different ways of calculating alcohol consumption, and failure to measure lifetime use or the pattern of alcohol intake.
AFLD and NAFLD also have many similarities in pathogenesis, histology and genetic factors since the genes PNPLA3 and TM6SF2 contribute to the progression of both AFLD and NAFLD). 4 Because of these confounding factors the real prevalence and incidence of NAFLD and NASH varies greatly in the general population.
We strongly believe that the nomenclature must be revised. Table 2 ).
| THE DIMENSION OF THE PROBLEM WORLDWIDE
There is a need to better define the current and future burden of for the first time in Italy by the Dionysos study 7 and recently confirmed by Younossi 8,9 who described some regional differences with the highest rates reported in South America and the Middle East, followed by Asia, the USA and Europe. • The definition and classification of primary NAFLD/ NASH must be revised and associated with the metabolic changes in the liver.
• The real prevalence of NAFL, NAFLD and NASH has not been clarified.
• The need for sensitive, affordable, and reliable non-invasive tests to diagnose and stage this disease is urgent.
Translational research may provide solutions. 
T A B L E 1 Actual classification of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)

| NATURAL HISTORY AND DISEASE BURDEN
To better understand the natural history and disease burden of this entity, NAFLD may be classified into two groups: NAFL or NASH with steatosis accompanied by inflammation, fibrosis and other changes. The odds of progression to advanced liver disease, including hepatic decompensation and hepatocellular carcinoma (HCC), are higher in patients with NASH than those with NAFL.
13
Progression to cirrhosis is characterized by the progression of the stages of fibrosis, and the stage of fibrosis has been linked to longterm clinical outcomes. 14 Most liver-related outcomes occur once cirrhosis has developed, except for HCC, which can occur without cirrhosis. 15, 16 The healthcare resources necessary to manage NAFLD increase markedly with the worsening of fibrosis, and especially once cirrhosis has developed. NASH is now one of the main causes of end-stage liver disease and HCC requiring liver transplantation in the US. 17, 18 Increasing age, obesity and DM have been clearly identified as risk factors for the progression to cirrhosis. 19 Patients with NASH have a high risk of both liver-related morbidity and mortality as well as metabolic comorbidities (10 × higher than the general population), cardiovascular disease and mortality (2 × higher than the general population), and cancer (particularly bowel and breast cancer). 8, 9 All potential extrahepatic complications are reported in Figure 1 .
Although there are no exact models to estimate the incidence and the disease burden of NAFLD in the next few years, the changing trends of obesity and diabetes (DM), suggest that this problem is increasing worldwide and might place a growing strain on healthcare systems.
| THE NEED FOR RELIABLE BIOMARKERS
Although the research on NAFLD biomarkers has advanced in the last two decades, there are still no reliable non-invasive markers for the diagnosis or the staging of this disease (NAFLD vs NASH). As mentioned above, the FLI 1 is probably the most popular score to diagnose FL in the literature. However, it was not designed to predict changes in FL status, and cannot be used to diagnose NASH.
Effective screening is essential due to the extensive number of NAFLD patients with potentially, 9 and there is an urgent need to develop a non-invasive method, particularly for large-scale NAFLD screening. 20 Non-invasive monitoring of hepatocyte apoptosis in the blood of patients with NAFLD has been proposed as a noninvasive biomarker and may help predict progression to cirrhosis and HCC. 9, 21 In addition, there is also a need to develop and validate a simple, F I G U R E 1 Extrahepatic complications of non-alcoholic fatty liver disease (FGF21); c) insulin-like growth factor 2 (IGF-2) and the epidermal growth factor receptor (EGFR). [25] [26] [27] [28] [29] These biomarkers are expected to improve the ability to stratify disease severity in NAFLD and may identify additional pathways to target for treatment. 28 However, despite several available studies, an accurate and reproducible noninvasive method to diagnose NAFLD/NASH, which could be used for screening in the general population or for patient follow-up has still not been identified. weight is needed to obtain a beneficial effect in the reversion of NASH (and fibrosis). Unfortunately, low patient compliance to this approach (even in highly motivated subjects) is the most difficult obstacle. 30, 31 Recent studies on bioactive food compounds are an interesting approach. [32] [33] [34] Although nutritional interventions are one of the most successful strategies for the management of NAFLD and NASH, more research is still needed to develop suitable treatment with high impact against these diseases. Thus, there is an urgent need to develop highly effective and safe therapeutic strategies for NASH.
| FUTURE PERSPECTIVES
Several experimental models have been characterized in the field of translational research to study the molecular mechanisms involved in the onset and progression of the disease. These cover a wide spectrum of variables, from a single cell to more complex systems such as ex-vivo or in-vivo models. In the past few years the latter have played an important role in the understanding of the pathophysiological mechanisms of the disease, and provided useful and detailed information on the cellular response to fatty acid overload and the crosstalk of injured hepatocytes with other hepatic cells, such as stellate cells. [35] [36] [37] However, it must be remembered that although the models may mimic the clinical scenario, any results obtained in the lab need to be validated and translated in the much more complex human system.
| WHAT NEXT?
Although it is clear that FL (either NAFLD or NASH) is significantly increasing in all the regions of the world, a precise estimation of the denominator of the equation clinically diagnosed FL/undiagnosed subjects is still lacking. This is mainly due to the lack of non-invasive, affordable tests that can be used worldwide to precisely define the number of affected individuals and to the confusing terminology which prevents reliable comparisons of series from different countries and institutions. As previously reported, FL is one element of the much more complex metabolic syndrome and it will probably be encountered in consultations for T2DM or cardiovascular diseases. Thus, FL and all related diseases should be managed by multidisciplinary teams. This coordinated effort will help determine the "denominator" of the equation and provide more focused and effective prevention.
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